Dipyridamole Shortage: What Providers and Prescribers Need to Know in 2026

Dipyridamole, an antiplatelet and vasodilator used in thromboembolism prophylaxis and pharmacological cardiac stress testing, has faced intermittent supply disruptions that affect both inpatient and outpatient settings. This briefing provides an overview of the current situation and practical guidance for managing patients who rely on this medication.

Shortage Timeline and Current Status

Injectable Dipyridamole (5 mg/mL): ASHP has listed Dipyridamole injection as experiencing shortage conditions. Hikma, a primary supplier of the 5 mg/mL, 10 mL vial formulation, reported supply disruptions without disclosing a specific cause. This directly impacts cardiac stress testing protocols, as IV Dipyridamole is a standard pharmacological stressor for patients who cannot exercise.

Oral Dipyridamole (25 mg, 50 mg, 75 mg tablets): While not formally listed as a national shortage, oral Dipyridamole availability has been inconsistent. This is largely driven by limited manufacturer participation, pharmacy stocking decisions, and broader generic supply chain vulnerabilities rather than a single precipitating event.

Aggrenox (Aspirin 25 mg / Dipyridamole ER 200 mg): The combination product has generally maintained better availability than standalone Dipyridamole, though it may carry higher costs and is not interchangeable for all indications.

Prescribing Implications

The Dipyridamole supply situation creates several clinical considerations:

For Patients on Oral Dipyridamole

• Heart valve replacement patients: Dipyridamole is FDA-approved as adjunctive therapy with warfarin for mechanical valve thromboembolism prophylaxis. If unavailable, consider whether the patient's anticoagulation regimen with warfarin alone provides adequate protection, particularly with close INR monitoring. The evidence base for dipyridamole's added benefit in this context is modest.
• Stroke prevention patients: Per AHA/ASA 2021 guidelines, Aspirin (50–325 mg daily), Clopidogrel (75 mg daily), and Aspirin/extended-release Dipyridamole (25/200 mg twice daily) are all recommended options for secondary prevention of non-cardioembolic ischemic stroke. Switching to Clopidogrel or Aspirin monotherapy represents an evidence-based alternative.

For Cardiac Stress Testing

If injectable Dipyridamole is unavailable, Regadenoson (Lexiscan) is the most widely available alternative pharmacological stressor. It has a simpler, fixed-dose administration protocol and shorter duration of effect. Adenosine remains another option but requires continuous infusion and carries a higher side effect burden. Coordinate with your nuclear cardiology or imaging department to confirm which agents are currently in stock.

The Availability Picture

Availability varies significantly by region and pharmacy type:

• Chain pharmacies may not stock Dipyridamole at low-volume locations. If a patient reports it as "out of stock," it may reflect an ordering issue rather than a true shortage.
• Independent pharmacies with multiple wholesaler relationships often have more success sourcing Dipyridamole. Consider recommending these to patients.
• Hospital pharmacies may have separate supply channels, particularly for the injectable formulation. Coordinate with your pharmacy and therapeutics committee on formulary alternatives during shortages.

Cost and Access Considerations

Cost can be a barrier for some patients, particularly those without insurance:

• Generic Dipyridamole cash price: $100–$160 for 60 tablets (75 mg) at retail.
• With discount cards (GoodRx, SingleCare): $22–$29 for the same quantity.
• Clopidogrel (as alternative): typically $10–$30/month with coupons, potentially a more cost-effective option.

No active manufacturer savings programs exist for generic Dipyridamole. Prescription Hope offers Aggrenox access at $70/month for eligible patients. NeedyMeds and RxAssist can help identify additional patient assistance resources.

Tools and Resources for Your Practice

Medfinder for Providers (medfinder.com/providers) allows you and your staff to quickly check which pharmacies in your area have Dipyridamole in stock. This can be integrated into your discharge or prescription workflow to direct patients to pharmacies that can fill their prescriptions immediately.

Additional resources:

• ASHP Drug Shortages — Monitor the current shortage list for the latest updates on Dipyridamole injectable and other affected medications.
• FDA Drug Shortage Database — Check for manufacturer status updates and estimated resolution timelines.
• AHA/ASA Guidelines — 2021 guideline update for secondary stroke prevention provides the evidence framework for alternative antiplatelet selection.

Looking Ahead

The structural factors driving Dipyridamole supply instability — limited manufacturers, thin margins, and supply chain concentration — are unlikely to resolve quickly. Providers should consider developing proactive protocols for their practices:

• Identify alternative antiplatelet regimens in advance for patients currently on Dipyridamole.
• Establish pharmacy relationships that can reliably source the medication.
• Educate patients about proactive refill strategies and the importance of not abruptly stopping antiplatelet therapy.

Final Thoughts

The Dipyridamole shortage underscores the broader fragility of the generic drug supply chain. By staying informed and maintaining flexible prescribing strategies, providers can minimize disruption to patient care. For real-time availability checking, visit Medfinder for Providers. For a step-by-step practice guide, see our article on helping patients find Dipyridamole in stock.